Security key
293602504
Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC)
CUSIP: 293602504
Q4 2024 13F Holders as of 31 Dec 2024
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 2,371,778
- Total 13F shares
- 140,823
- Share change
- +140,823
- Total reported value
- $1,145,879
- Price per share
- $8.14
- Number of holders
- 8
- Value change
- +$1,145,879
- Number of buys
- 8
Report period
Q4 2024
Institutions
8
Top holders
8
ENSC full security history
Newer quarter: Q1 2025
Ensysce Biosciences, Inc. SEC filings
Ensysce Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 293602504
Recent filing periods:
Top shareholders of ENSC - Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Anson Funds Management LP |
13F
13D/G
|
Company |
2.1%
from 13D/G
|
983,518
|
$236,044 | — | 30 Sep 2024 | |
| SABBY MANAGEMENT, LLC |
13F
|
Company |
5.9%
|
1,162,592
|
$279,022 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0.57%
|
112,682
|
$27,044 | — | 30 Sep 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
46,072
|
$11,057 | — | 30 Sep 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.12%
|
23,605
|
$5,665 | — | 30 Sep 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.12%
|
23,558
|
$5,000 | — | 30 Sep 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.11%
|
22,400
|
$5,376 | — | 30 Sep 2024 | |
| Cerity Partners LLC |
13F
|
Company |
0.11%
|
21,426
|
$5,142 | — | 30 Sep 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.09%
|
18,175
|
$4,362 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.03%
|
6,454
|
$1,549 | — | 30 Sep 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
975
|
$234 | — | 30 Sep 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
69
|
$17 | — | 30 Sep 2024 | |
| A. Lorne Weil |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,868,005
|
$1,868,005 | — | 30 Jun 2021 | |
| Daniel B. Silvers |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,754,497
|
$1,754,497 | — | 30 Jun 2021 | |
| William H. Chang |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
2,630,640
mixed-class rows
|
$1,267,451 | — | 23 Jun 2022 | |
| Bob G. Gower |
3/4/5
|
Director |
—
class O/S missing
|
1,222,682
|
$597,036 | — | 02 Mar 2023 | |
| Lynn Kirkpatrick |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
2,898,790
mixed-class rows
|
$186,458 | — | 25 May 2022 | |
| Eric Carrera |
3/4/5
|
Former officer |
—
class O/S missing
|
30,000
|
$30,000 | — | 30 Jun 2021 | |
| George Peng |
3/4/5
|
Former officer |
—
class O/S missing
|
15,000
|
$15,000 | — | 30 Jun 2021 | |
| Richard Chester Wright |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
987,750
|
— | — | 30 Jun 2021 | |
| Linda Pestano |
3/4/5
|
Chief Development Officer |
—
class O/S missing
|
200,000
|
— | — | 04 Feb 2022 | |
| Andrew Benton |
3/4/5
|
Director |
—
class O/S missing
|
100,850
|
— | — | 23 Jun 2022 | |
| Steven Robert Martin |
3/4/5
|
Director |
—
class O/S missing
|
100,850
|
— | — | 23 Jun 2022 | |
| David Carl Humphrey |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
80,000
|
— | — | 17 Feb 2022 | |
| William K. Schmidt |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
69,142
|
— | — | 30 Jun 2021 | |
| Kevin Geoffrey Birkett |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
50,000
|
— | — | 17 Feb 2022 | |
| Adam Levin |
3/4/5
|
Director |
—
class O/S missing
|
35,000
|
— | — | 23 Jun 2022 | |
| Curtis Rosebraugh |
3/4/5
|
Director |
—
class O/S missing
|
35,000
|
— | — | 23 Jun 2022 | |
| Lee M. Rauch |
3/4/5
|
Director |
—
class O/S missing
|
35,000
|
— | — | 23 Jun 2022 |
Institutional Holders of Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) as of Q4 2024
As of 31 Dec 2024,
Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) was held by
8 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
140,823 shares.
The largest 8 holders included
PERCEPTIVE ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., FNY Investment Advisers, LLC, UBS Group AG, Tower Research Capital LLC (TRC), BlackRock, Inc., MORGAN STANLEY, and BANK OF AMERICA CORP /DE/.
This page lists
8
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q4 2025 Across Filers
Q4 2025 holders
17
Q4 2024 holders
8
Holder diff
-9
| Investor | Q4 2025 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.